A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of rofecoxib in familial adenomatous polyposis (FAP)

Trial Profile

A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of rofecoxib in familial adenomatous polyposis (FAP)

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Rofecoxib (Primary)
  • Indications Colorectal cancer; Familial adenomatous polyposis
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 05 Dec 2006 Status change
    • 01 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top